Preanalytical variables that affect the outcome of cell-free DNA measurements

References

• Aucamp J, Bronkhorst AJ, Badenhorst CPS, et al. The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature. Biol Rev. 2018;93(3):1649–1683.
   PubMed Web of Science ®Google Scholar
• Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016;35(3):347–376.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087.
   PubMedGoogle Scholar
• Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.
   PubMed Web of Science ®Google Scholar
• Christina Fan H, Gu W, Wang J, et al. Non-invasive prenatal measurement of the fetal genome. Nature. 2012;487(7407):320–324.
   PubMed Web of Science ®Google Scholar
• van Dessel LF, Vitale SR, Helmijr JCA, et al. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms. Mol Oncol. 2019;13(2):392–402.
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–554.
   PubMed Web of Science ®Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555.
   PubMed Web of Science ®Google Scholar
• Brown P. The Cobas®EGFR Mutation Test v2 assay. Future Oncol. 2016;12(4):451–452.
   PubMed Web of Science ®Google Scholar
• Lowes LE, Bratman SV, Dittamore R, et al. Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation. Int J Mol Sci. 2016;17(9):1505.
   PubMed Web of Science ®Google Scholar
• Warren JD, Xiong W, Bunker AM, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9(1):133.
   PubMedGoogle Scholar
• FDA approves alpelisib for metastatic breast cancer; 2019 [cited 2020 Feb 22]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer
   Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor – positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940.
   PubMed Web of Science ®Google Scholar
• Allyse M, Minear MA, Berson E, et al. Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health. 2015;7:113–126.
   PubMed Web of Science ®Google Scholar
• Aravanis AM, Lee M, Klausner RD. Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell. 2017;168(4):571–574.
   PubMed Web of Science ®Google Scholar
• Meddeb R, Pisareva E, Thierry AR. Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem. 2019;65(5):623–633.
   PubMed Web of Science ®Google Scholar
• Malentacchi F, Pizzamiglio S, Verderio P, et al. Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience. Clin Chem Lab Med. 2015;53(12):1935–1942.
   PubMed Web of Science ®Google Scholar
• Haselmann V, Ahmad-Nejad P, Geilenkeuser WJ, et al. Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). Clin Chem Lab Med. 2018;56(2):220–228.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Aucamp J, Pretorius PJ. Cell-free DNA: preanalytical variables. Clin Chim Acta. 2015;450:243–253.
   PubMed Web of Science ®Google Scholar
• El Messaoudi S, Rolet F, Mouliere F, et al. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta. 2013;424:222–230.
   PubMed Web of Science ®Google Scholar
• Zavridou M, Mastoraki S, Strati A, et al. Evaluation of preanalytical conditions and implementation of quality control steps for reliable gene expression and DNA methylation analyses in liquid biopsies. Clin Chem. 2018;64(10):1522–1533.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.
   PubMed Web of Science ®Google Scholar
• Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198.
   PubMed Web of Science ®Google Scholar
• Gorges TM, Schiller J, Schmitz A, et al. Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA. Biomarkers. 2012;17(6):498–506.
   PubMed Web of Science ®Google Scholar
• Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res. 2010;38(18):6159–6175.
   PubMed Web of Science ®Google Scholar
• Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16(1):166.
   PubMedGoogle Scholar
• Bronkhorst AJ, Ungerer V, Holdenrieder S. Early detection of cancer using circulating tumor DNA: biological, physiological and analytical considerations. Crit Rev Clin Lab Sci. 2019. DOI:10.1080/10408363.2019.1700902
   PubMed Web of Science ®Google Scholar
• Deichmann R, Radsak M, Tug S, et al. Exercise-induced increases in cell free DNA in human plasma originate predominantly from cells of the haematopoietic lineage. Exerc Immunol Rev. 2015;21(27):164–173.
   PubMedGoogle Scholar
• Lehmann-Werman R, Neiman D, Zemmour H, et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 2016;113(13):E1826–E1834.
   PubMed Web of Science ®Google Scholar
• Lui YYN, Chik KW, Chiu RWK, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002;48(3):421–427.
   PubMed Web of Science ®Google Scholar
• Wu DC, Lambowitz AM. Facile single-stranded DNA sequencing of human plasma DNA via thermostable group II intron reverse transcriptase template switching. Sci Rep. 2017;7(1):8421.
   PubMedGoogle Scholar
• Wong FC, Sun K, Jiang P, et al. Cell-free DNA in maternal plasma and serum: a comparison of quantity, quality and tissue origin using genomic and epigenomic approaches. Clin Biochem. 2016;49(18):1379–1386.
   PubMed Web of Science ®Google Scholar
• Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–E5512.
   PubMed Web of Science ®Google Scholar
• Zemmour H, Planer D, Magenheim J, et al. Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA. Nat Commun. 2018;9(1):1443.
   PubMedGoogle Scholar
• Moss J, Magenheim J, Neiman D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun. 2018;9(1):5068.
   PubMed Web of Science ®Google Scholar
• Tang W, Wan S, Yang Z, et al. Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics. 2018;34(3):398–406.
   PubMed Web of Science ®Google Scholar
• Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1–2):57–68.
   PubMed Web of Science ®Google Scholar
• Ulz P, Thallinger GG, Auer M, et al. Inferring expressed genes by whole-genome sequencing of plasma DNA. Nat Genet. 2016;48(10):1273–1278.
   PubMed Web of Science ®Google Scholar
• Ulz P, Perakis S, Zhou Q, et al. Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nat Commun. 2019;10(1):4666.
   PubMedGoogle Scholar
• Guo S, Diep D, Plongthongkum N, et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet. 2017;49(4):635–642.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Karpievitch YV, Eichten SR, et al. HOME: a histogram based machine learning approach for effective identification of differentially methylated regions. BMC Bioinformatics. 2019;20(1):253.
   PubMedGoogle Scholar
• Moran S, Martinez-Cardus A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(10):1386–1395.
   PubMed Web of Science ®Google Scholar
• Kang S, Li Q, Chen Q, et al. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. Genome Biol. 2017;18(1):53.
   PubMedGoogle Scholar
• Kundaje A, Meuleman W, Ernst J, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015;518(7539):317–330.
   PubMed Web of Science ®Google Scholar
• Fernandez AF, Assenov Y, Martin-Subero JI, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 2012;22(2):407–419.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, Stieber P. Apoptotic markers in cancer. Clin Biochem. 2004;37(7):605–617.
   PubMed Web of Science ®Google Scholar
• Nagata S, Nagase H, Kawane K, et al. Degradation of chromosomal DNA during apoptosis. Cell Death Differ. 2003;10(1):108–116.
   PubMed Web of Science ®Google Scholar
• Formichi P, Radi E, Battisti C, et al. Human fibroblasts undergo oxidative stress-induced apoptosis without internucleosomal DNA fragmentation. J Cell Physiol. 2006;208(2):289–297.
   PubMed Web of Science ®Google Scholar
• Delgado PO, Alves BC, Gehrke FdeS, et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumor Biol. 2013;34(2):983–986.
   PubMed Web of Science ®Google Scholar
• Jiang WW, Zahurak M, Goldenberg D, et al. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer. 2006;119(11):2673–2676.
   PubMed Web of Science ®Google Scholar
• Umetani N, Hiramatsu S, Hoon DS. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann NY Acad Sci. 2006;1075(1):299–307.
   PubMedGoogle Scholar
• Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003;63(14):3966–3968.
   PubMed Web of Science ®Google Scholar
• Mair R, Mouliere F, Smith CG, et al. Measurement of plasma cell-free mitochondrial tumor DNA improves detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Res. 2019;79(1):220–230.
   PubMed Web of Science ®Google Scholar
• Boyapati RK, Tamborska A, Dorward DA, et al. Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. F1000Res. 2017;6:169.
   PubMedGoogle Scholar
• Zhang R, Nakahira K, Guo X, et al. Very short mitochondrial DNA fragments and heteroplasmy in human plasma. Sci Rep. 2016;6(1):36097.
   PubMedGoogle Scholar
• Zhong S, Ng MC, Lo YM, et al. Presence of mitochondrial tRNA(Leu(UUR)) A to G 3243 mutation in DNA extracted from serum and plasma of patients with type 2 diabetes mellitus. J Clin Pathol. 2000;53(6):466–469.
   PubMed Web of Science ®Google Scholar
• Panagopoulou M, Karaglani M, Balgkouranidou I, et al. Circulating cell-free DNA release in vitro: kinetics, size profiling, and cancer-related gene methylation. J Cell Physiol. 2019;234(8):14079–14089.
   PubMed Web of Science ®Google Scholar
• Aucamp J, Bronkhorst AJ, Peters DL, et al. Kinetic analysis, size profiling, and bioenergetic association of DNA released by selected cell lines in vitro. Cell Mol Life Sci. 2017;74(14):2689–2707.
   PubMed Web of Science ®Google Scholar
• Wang W, Kong P, Ma G, et al. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. Oncotarget. 2017;8(26):43180–43191.
   PubMedGoogle Scholar
• Bronkhorst AJ, Wentzel JF, Aucamp J, et al. Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2016;1863(1):157–165.
   PubMed Web of Science ®Google Scholar
• Gahan PB, Stroun M. The virtosome—a novel cytosolic informative entity and intercellular messenger. Cell Biochem Funct. 2010;28(7):529–538.
   PubMed Web of Science ®Google Scholar
• Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313(1–2):139–142.
   PubMed Web of Science ®Google Scholar
• Stroun M, Anker P, Beljanski M, et al. Presence of RNA in the nucleoprotein complex spontaneously released by human lymphocytes and frog auricles in culture. Cancer Res. 1978;38(10):3546–3554.
   PubMed Web of Science ®Google Scholar
• Anker P, Stroun M, Maurice PA. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res. 1975;35(9):2375–2382.
   PubMed Web of Science ®Google Scholar
• Stroun M, Anker P. Nucleic acids spontaneously released by living frog auricles. Biochem J. 1972;128(3):100P–101P.
   PubMed Web of Science ®Google Scholar
• Borenstein S, Ephrati-Elizur E. Spontaneous release of DNA in sequential genetic order by Bacillus subtilis. J Mol Biol. 1969;45(1):137–152.
   PubMed Web of Science ®Google Scholar
• Bronkhorst AJ, Wentzel JF, Ungerer V, et al. Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cells. Tumour Biol. 2018. DOI:10.1177/1010428318801190
   PubMedGoogle Scholar
• Kumar P, Dillon LW, Shibata Y, et al. Normal and cancerous tissues release extrachromosomal circular DNA (eccDNA) into the circulation. Mol Cancer Res. 2017;15(9):1197–1205.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang F, Du M, et al. Molecular characterization of cell-free eccDNAs in human plasma. Sci Rep. 2017;7(1):10968.
   PubMedGoogle Scholar
• Fernando MR, Jiang C, Krzyzanowski GD, et al. New evidence that a large proportion of human blood plasma cell-free DNA is localized in exosomes. PLoS One. 2017;12(8):e0183915.
   PubMed Web of Science ®Google Scholar
• Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;24(6):766–769.
   PubMed Web of Science ®Google Scholar
• Ronquist G. Prostasomes are mediators of intercellular communication: from basic research to clinical implications. J Intern Med. 2012;271(4):400–413.
   PubMed Web of Science ®Google Scholar
• Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.
   PubMed Web of Science ®Google Scholar
• Hellwig S, Nix DA, Gligorich KM, et al. Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing. PLoS One. 2018;13(7):e0197333.
   PubMed Web of Science ®Google Scholar
• Underhill HR, Kitzman JO, Hellwig S, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162.
   PubMed Web of Science ®Google Scholar
• Jiang P, Chan CW, Chan KC, et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015;112(11):E1317–E1325.
   PubMed Web of Science ®Google Scholar
• Mouliere F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011;6(9):e23418.
   PubMed Web of Science ®Google Scholar
• Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6(1):8839.
   PubMedGoogle Scholar
• Alekseeva LA, Mironova NL, Brenner EV, et al. Alteration of the exDNA profile in blood serum of LLC-bearing mice under the decrease of tumour invasion potential by bovine pancreatic DNase I treatment. PLoS One. 2017;12(2):e0171988.
   PubMed Web of Science ®Google Scholar
• Tamkovich SN, Cherepanova AV, Kolesnikova EV, et al. Circulating DNA and DNase activity in human blood. Ann NY Acad Sci. 2006;1075(1):191–196.
   PubMedGoogle Scholar
• Serpas L, Chan RWY, Jiang P, et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc Natl Acad Sci U S A. 2019;116(2):641–649.
   PubMed Web of Science ®Google Scholar
• Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–16373.
   PubMed Web of Science ®Google Scholar
• Chused TM, Steinberg AD, Talal N. The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol. 1972;12(4):465–476.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Melnikova VO, Karlovich C, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11(10):1690–1700.
   PubMed Web of Science ®Google Scholar
• Miranda KC, Bond DT, McKee M, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010;78(2):191–199.
   PubMed Web of Science ®Google Scholar
• Botezatu I, Serdyuk O, Potapova G, et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000;46(8):1078–1084.
   PubMed Web of Science ®Google Scholar
• Tamkovich S, Laktionov P. Cell-surface-bound circulating DNA in the blood: biology and clinical application. IUBMB Life. 2019;71(9):1201–1210.
   PubMed Web of Science ®Google Scholar
• Yao W, Mei C, Nan X, et al. Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study. Gene. 2016;590(1):142–148.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990.
   PubMed Web of Science ®Google Scholar
• To EW, Chan KC, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res. 2003;9(9):3254–3259.
   PubMed Web of Science ®Google Scholar
• Van Der Vaart M, Pretorius PJ. Circulating DNA: its origin and fluctuation. Ann NY Acad Sci. 2008;1137(1):18–26.
   PubMedGoogle Scholar
• Brahmer A, Neuberger E, Esch-Heisser L, et al. Platelets, endothelial cells and leukocytes contribute to the exercise-triggered release of extracellular vesicles into the circulation. J Extracell Vesicles. 2019;8(1):1615820.
   PubMed Web of Science ®Google Scholar
• Schmidt B, Fleischhacker M. Is liquid biopsy ready for the litmus test and what has been achieved so far to deal with pre-analytical issues? Transl Cancer Res. 2018;7(S2):S130–S139.
   Google Scholar
• Khier S, Lohan L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature. Future Sci OA. 2018;4(4):FSO295.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Taenny P, Petry J, et al. Circulating, cell-free DNA as a marker for exercise load in intermittent sports. PLoS One. 2018;13(1):e0191915.
   PubMed Web of Science ®Google Scholar
• Breitbach S, Sterzing B, Magallanes C, et al. Direct measurement of cell-free DNA from serially collected capillary plasma during incremental exercise. J Appl Physiol (1985). 2014;117(2):119–130.
   PubMed Web of Science ®Google Scholar
• Fatouros IG, Jamurtas AZ, Nikolaidis MG, et al. Time of sampling is crucial for measurement of cell-free plasma DNA following acute aseptic inflammation induced by exercise. Clin Biochem. 2010;43(16–17):1368–1370.
   PubMed Web of Science ®Google Scholar
• Atamaniuk J, Vidotto C, Kinzlbauer M, et al. Cell-free plasma DNA and purine nucleotide degradation markers following weightlifting exercise. Eur J Appl Physiol. 2010;110(4):695–701.
   PubMed Web of Science ®Google Scholar
• Atamaniuk J, Stuhlmeier KM, Vidotto C, et al. Effects of ultra-marathon on circulating DNA and mRNA expression of pro- and anti-apoptotic genes in mononuclear cells. Eur J Appl Physiol. 2008;104(4):711–717.
   PubMed Web of Science ®Google Scholar
• Beiter T, Fragasso A, Hudemann J, et al. Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. Clin Chem. 2011;57(4):633–636.
   PubMed Web of Science ®Google Scholar
• Madsen AT, Hojbjerg JA, Sorensen BS, et al. Day-to-day and within-day biological variation of cell-free DNA. EBioMedicine. 2019;49:284–290.
   PubMed Web of Science ®Google Scholar
• Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res. 1972;42(1):201–206.
   PubMed Web of Science ®Google Scholar
• Korabecna M, Horinek A, Bila N, et al. Circadian rhythmicity and clearance of cell-free DNA in human plasma. In: Gahan P, editor. Circulating nucleic acids in plasma and serum. Dordrecht: Springer; 2010. p. 195–198.
   Google Scholar
• Meddeb R, Dache ZAA, Thezenas S, et al. Quantifying circulating cell-free DNA in humans. Sci Rep. 2019;9(1):5220.
   PubMedGoogle Scholar
• Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–484.
   PubMed Web of Science ®Google Scholar
• Mandel P. Les acides nucleiques du plasma sanguin chez 1 homme. CR Seances Soc Biol Fil. 1948;142:241–243.
   PubMedGoogle Scholar
• Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–650.
   PubMed Web of Science ®Google Scholar
• Peng M, Chen C, Hulbert A, et al. Non-blood circulating tumor DNA detection in cancer. Oncotarget. 2017;8(40):69162–69173.
   PubMedGoogle Scholar
• Sidransky D, Tokino T, Kinzler KW, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science. 1992;256(5053):102–105.
   PubMed Web of Science ®Google Scholar
• Birkenkamp-Demtröder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol. 2018;73(4):535–540.
   PubMed Web of Science ®Google Scholar
• Rentsch CA, Müller DC, Ruiz C, et al. Moving towards minimally invasive genomically based diagnosis and monitoring of bladder cancer. Eur Urol. 2016;70(1):83–84.
   PubMed Web of Science ®Google Scholar
• Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4.
   PubMed Web of Science ®Google Scholar
• Nair N, Camacho-Vanegas O, Rykunov D, et al. Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study. PLoS Med. 2016;13(12):e1002206.
   PubMed Web of Science ®Google Scholar
• Ross-Innes CS, Chettouh H, Achilleos A, et al. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(1):23–31.
   PubMed Web of Science ®Google Scholar
• Patel KM, Tsui D. The translational potential of circulating tumour DNA in oncology. Clin Biochem. 2015;48(15):957–961.
   PubMed Web of Science ®Google Scholar
• Angert RM, LeShane ES, Yarnell RW, et al. Cell-free fetal DNA in the cerebrospinal fluid of women during the peripartum period. Am J Obstet Gynecol. 2004;190(4):1087–1090.
   PubMed Web of Science ®Google Scholar
• Taback B, O'Day SJ, Hoon DSB. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann NY Acad Sci. 2004;1022(1):17–24.
   PubMedGoogle Scholar
• Thijssen MAMA, Swinkels DW, Ruers TJM, et al. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 2002;22(1A):421–425.
   PubMed Web of Science ®Google Scholar
• Lee T-H, Montalvo L, Chrebtow V, et al. Higher concentrations of genomic DNA found in serum than in plasma. Transfusion. 2001;41(2):276–282.
   PubMed Web of Science ®Google Scholar
• Steinman D, Mt SS, City UNY, et al. Free DNA in serum and plasma from normal adults. J Clin Invest. 1975;56(2):512–515.
   PubMed Web of Science ®Google Scholar
• Jung M, Klotzek S, Lewandowski M, et al. Changes in concentration of DNA in serum and plasma during storage of blood samples. Clin Chem. 2003;49(6):1028–1029.
   PubMed Web of Science ®Google Scholar
• Lui YYN, Chik K-W, Lo Y. Does centrifugation cause the ex vivo release of DNA from blood cells? Clin Chem. 2002;48(11):2074–2076.
   PubMed Web of Science ®Google Scholar
• Lo YMD, Tein MSC, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998;62(4):768–775.
   PubMed Web of Science ®Google Scholar
• Elshimali YI, Khaddour H, Sarkissyan M, et al. The clinical Utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013;14(9):18925–18958.
   PubMed Web of Science ®Google Scholar
• van der Vaart M, Pretorius PJ. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem. 2010;43(1–2):26–36.
   PubMed Web of Science ®Google Scholar
• Board RE, Williams VS, Knight L, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann NY Acad Sci. 2008;1137(1):98–107.
   PubMedGoogle Scholar
• Chiu RWK, Lui WB, El-Sheikhah A, et al. Comparison of protocols for extracting circulating DNA and RNA from maternal plasma. Clin Chem. 2005;51(11):2209–2210.
   PubMed Web of Science ®Google Scholar
• Chan AKC, Chiu RWK, Lo Y. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann Clin Biochem. 2003;40(2):122–130.
   PubMedGoogle Scholar
• Lo YMD, Hung ECW, Chiu R. Detection of circulating fetal nucleic acids: a review of methods and applications. J Clin Path. 2009;62(4):308–313.
   PubMed Web of Science ®Google Scholar
• Soo J, Kurtz DM, Jin M, et al. Comparison of circulating tumor DNA recovery from plasma and serum. Blood. 2017;130:2756.
   Web of Science ®Google Scholar
• Kumar M, Choudhury Y, Ghosh SK, et al. Application and optimization of minimally invasive cell-free DNA techniques in oncogenomics. Tumor Biol. 2018;40(2):1–12.
   Google Scholar
• Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 2004;22(20):4157–4164.
   PubMed Web of Science ®Google Scholar
• Vallée A, Marcq M, Bizieux A, et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer. 2013;82(2):373–374.
   PubMed Web of Science ®Google Scholar
• Andersen RF, Spindler KG, Jakobsen A, et al. 479 Plasma is superior to serum for CfDNA mutation detection and monitoring. Eur J Cancer. 2012;48:148–149.
   Web of Science ®Google Scholar
• Morgan SR, Whiteley J, Donald E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol. 2012;5:15–22.
   PubMedGoogle Scholar
• Rasmussen L, Herzog M, Rømer E, et al. Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9Me3. Scand J Clin Lab Invest. 2016;76(6):448–453.
   PubMed Web of Science ®Google Scholar
• Tatsumi N, Miwa S, Lewis SM. Specimen collection, storage, and transmission to the laboratory for hematological tests. Int J Hematol. 2002;75(3):261–268.
   PubMed Web of Science ®Google Scholar
• Enko D, Halwachs-Baumann G, Kriegshäuser G. Plasma free DNA: evaluation of temperature-associated storage effects observed for Roche cell-free DNA collection tubes. Biochem Med (Online). 2019;29(1):153–156.
   Web of Science ®Google Scholar
• Bowen RAR, Remaley AT. Interferences from blood collection tube components on clinical chemistry assays. Biochem Med. 2014;24(1):31–44.
   PubMed Web of Science ®Google Scholar
• Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med. 2001;39(7):596–605.
   PubMed Web of Science ®Google Scholar
• Nikolaev S, Lemmens L, Koessler T, et al. Circulating tumoral DNA: preanalytical validation and quality control in a diagnostic laboratory. Anal Biochem. 2018;542:34–39.
   PubMed Web of Science ®Google Scholar
• Barnaby DP, Wollowitz A, White D, et al. Generalizability and effectiveness of butterfly phlebotomy in reducing hemolysis. Acad Emerg Med. 2016;23(2):204–207.
   PubMed Web of Science ®Google Scholar
• Wollowitz A, Bijur PE, Esses D, et al. Use of butterfly needles to draw blood is independently associated with marked reduction in hemolysis compared to intravenous catheter. Acad Emerg Med. 2013;20(11):1151–1155.
   PubMed Web of Science ®Google Scholar
• Lippi G, Salvagno GL, Montagnana M, et al. Influence of the needle bore size used for collecting venous blood samples on routine clinical chemistry testing. Clin Chem Lab Med. 2006;44(8):1009–1014.
   PubMed Web of Science ®Google Scholar
• Moureau NL. Drawing blood through a central venous catheter. Nursing. 2004;34(2):28.
   PubMedGoogle Scholar
• Barra GB, Santa Rita TH, Vasques JA, et al. EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples. Clin Biochem. 2015;48(15):976–981.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Jewell DP, Welsh K, et al. Effect of heparin reaction. Lancet. 1994;343(8911):1509–1510.
   PubMed Web of Science ®Google Scholar
• Lam NYL, Rainer TH, Chiu RWK, et al. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem. 2004;50(1):256–257.
   PubMed Web of Science ®Google Scholar
• van Dessel LF, Beije N, Helmijr JCA, et al. Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions. Mol Oncol. 2017;11(3):295–304.
   PubMed Web of Science ®Google Scholar
• Norton SE, Luna KK, Lechner JM, et al. A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J Clin Lab Anal. 2013;27(4):305–311.
   PubMed Web of Science ®Google Scholar
• Norton SE, Lechner JM, Williams T, et al. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. 2013;46(15):1561–1565.
   PubMed Web of Science ®Google Scholar
• Markus H, Contente-Cuomo T, Farooq M, et al. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018;8(1):7375.
   PubMedGoogle Scholar
• Grölz D, Hauch S, Schlumpberger M, et al. Liquid biopsy preservation solutions for standardized pre-analytical workflows—venous whole blood and plasma. Curr Pathobiol Rep. 2018;6(4):275–286.
   PubMedGoogle Scholar
• Parpart-Li S, Bartlett B, Popoli M, et al. The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res. 2017;23(10):2471–2477.
   PubMed Web of Science ®Google Scholar
• Warton K, Yuwono NL, Cowley MJ, et al. Evaluation of Streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther. 2017;21(5):563–570.
   PubMed Web of Science ®Google Scholar
• Wong D, Moturi S, Angkachatchai V, et al. Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem. 2013;46(12):1099–1104.
   PubMed Web of Science ®Google Scholar
• Fernando MR, Chen K, Norton S, et al. A new methodology to preserve the original proportion and integrity of cell-free fetal DNA in maternal plasma during sample processing and storage. Prenat Diagn. 2010;30(5):418–424.
   PubMed Web of Science ®Google Scholar
• Barrett AN, Zimmermann BG, Wang D, et al. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One. 2011;6(10):e25202.
   PubMed Web of Science ®Google Scholar
• Medina Diaz I, Nocon A, Mehnert DH, et al. Performance of Streck cfDNA blood collection tubes for liquid biopsy testing. PLoS One. 2016;11(11):e0166354.
   PubMed Web of Science ®Google Scholar
• Jeong T-D, Kim MH, Park S, et al. Effects of pre-analytical variables on cell-free DNA extraction for liquid biopsy. Lab Med Online. 2019;9(2):45–56.
   Google Scholar
• Risberg B, Tsui DWY, Biggs H, et al. Effects of collection and processing procedures on plasma circulating cell-free DNA from cancer patients. J Mol Diagn. 2018;20(6):883–892.
   PubMed Web of Science ®Google Scholar
• Hidestrand M, Stokowski R, Song K, et al. Influence of temperature during transportation on cell-free DNA analysis. Fetal Diagn Ther. 2012;31(2):122–128.
   PubMed Web of Science ®Google Scholar
• Wang Q, Cai Y, Brady P, et al. Real-time PCR evaluation of cell-free DNA subjected to various storage and shipping conditions. Genet Mol Res. 2015;14(4):12797–12804.
   PubMed Web of Science ®Google Scholar
• Toro PV, Erlanger B, Beaver JA, et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. Clin Biochem. 2015;48(15):993–998.
   PubMed Web of Science ®Google Scholar
• Xue X, Teare MD, Holen I, et al. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta. 2009;404(2):100–104.
   PubMed Web of Science ®Google Scholar
• Sherwood JL, Corcoran C, Brown H, et al. Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS One. 2016;11(2):e0150197.
   PubMed Web of Science ®Google Scholar
• Schmidt B, Reinicke D, Reindl I, et al. Liquid biopsy – performance of the PAXgene® blood ccfDNA tubes for the isolation and characterization of cell-free plasma DNA from tumor patients. Clin Chim Acta. 2017;469(March):94–98.
   PubMedGoogle Scholar
• Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol. 2016;10(4):566–574.
   PubMed Web of Science ®Google Scholar
• Kang Q, Henry NL, Paoletti C, et al. Comparative analysis of circulating tumor DNA stability in K3EDTA, Streck, and CellSave blood collection tubes. Clin Biochem. 2016;49(18):1354–1360.
   PubMed Web of Science ®Google Scholar
• Denis MG, Knol A-C, Théoleyre S, et al. Efficient detection of BRAF mutation in plasma of patients after long-term storage of blood in cell-free DNA blood collection tubes. Clin Chem. 2015;61(6):886–888.
   PubMed Web of Science ®Google Scholar
• Alidousty C, Brandes D, Heydt C, et al. Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing. J Mol Diagn. 2017;19(5):801–804.
   PubMed Web of Science ®Google Scholar
• Parackal S, Zou D, Day R, et al. Comparison of Roche cell-free DNA collection tubes to Streck cell-free DNA BCT s for sample stability using healthy volunteers. Pract Lab Med. 2019;16:e00125.
   PubMedGoogle Scholar
• Gahlawat AW, Lenhardt J, Witte T, et al. Evaluation of storage tubes for combined analysis of circulating nucleic acids in liquid biopsies. Int J Mol Sci. 2019;20(3):704.
   Web of Science ®Google Scholar
• Swinkels DW, Wiegerinck E, Steegers EAP, et al. Effects of blood-processing protocols on cell-free DNA quantification in plasma 4. Clin Chem. 2003;49(3):525–526.
   PubMed Web of Science ®Google Scholar
• Johansson G, Andersson D, Filges S, et al. Considerations and quality controls when analyzing cell-free tumor DNA. Biomol Detect Quantif. 2019;17:100078.
   PubMedGoogle Scholar
• Jen JIN, Wu LI, Sidransky D. An Overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann NY Acad Sci. 2006;906(1):8–12.
   Google Scholar
• Garcia J, Dusserre E, Cheynet V, et al. Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study. Oncotarget. 2017;8(50):87980–87996.
   PubMedGoogle Scholar
• Angert RM, LeShane ES, Lo YMD, et al. Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 hours after collection: analysis of first- and third-trimester samples. Clin Chem. 2003;49(1):195–198.
   PubMed Web of Science ®Google Scholar
• Müller SP, Bartels I, Stein W, et al. Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days. Prenat Diagn. 2011;31(13):1300–1304.
   PubMed Web of Science ®Google Scholar
• Clausen FB, Jakobsen TR, Rieneck K, et al. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD. PLoS One. 2013;8(10):e76990.
   PubMed Web of Science ®Google Scholar
• van Ginkel JH, van den Broek DA, van Kuik J, et al. Preanalytical blood sample workup for cell-free DNA analysis using Droplet digital PCR for future molecular cancer diagnostics. Cancer Med. 2017;6(10):2297–2307.
   PubMed Web of Science ®Google Scholar
• Chiu RWK, Poon LLM, Lau TK, et al. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem. 2001;47(9):1607–1613.
   PubMed Web of Science ®Google Scholar
• Holmberg RC, Gindlesperger A, Stokes T, et al. Akonni TruTip® and Qiagen® methods for extraction of fetal circulating DNA – evaluation by real-time and digital PCR. PLoS One. 2013;8(8):e73068.
   PubMed Web of Science ®Google Scholar
• Barrett AN, Thadani HA, Laureano-Asibal C, et al. Stability of cell-free DNA from maternal plasma isolated following a single centrifugation step. Prenat Diagn. 2014;34(13):1283–1288.
   PubMed Web of Science ®Google Scholar
• Fernando MR, Jiang C, Krzyzanowski GD, et al. Analysis of human blood plasma cell-free DNA fragment size distribution using EvaGreen chemistry based droplet digital PCR assays. Clin Chim Acta. 2018;483:39–47.
   PubMed Web of Science ®Google Scholar
• Rainone A, Troise A, Morelli CD, et al. Comparing methods for isolation of circulating-DNA (C-DNA). Implication of C-DNA as biomarker in the cancer. WCRJ. 2014;1(4):e384.
   Google Scholar
• Ammerlaan W, Trezzi JP, Lescuyer P, et al. Method validation for preparing serum and plasma samples from human blood for downstream proteomic, metabolomic, and circulating nucleic acid-based applications. Biopreserv Biobank. 2014;12(4):269–280.
   PubMed Web of Science ®Google Scholar
• Cavallone L, Aldamry M, Lafleur J, et al. A study of pre-analytical variables and optimization of extraction method for circulating tumor DNA measurements by digital droplet PCR. Cancer Epidemiol Biomarkers Prev. 2019;28(5):909–916.
   PubMed Web of Science ®Google Scholar
• Diefenbach RJ, Lee JH, Kefford RF, et al. Evaluation of commercial kits for purification of circulating free DNA. Cancer Genet. 2018;228–229:21–27.
   PubMed Web of Science ®Google Scholar
• Nagel D, Fersching DMI, Siegele B, et al. Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta. 2011;412(23–24):2085–2088.
   PubMed Web of Science ®Google Scholar
• Kloten V, Ruchel N, Bruchle NO, et al. Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR. Oncotarget. 2017;8(49):86253–86263.
   PubMedGoogle Scholar
• Lee HJ, Jeon SH, Seo JS, et al. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure. Biomaterials. 2016;101:251–257.
   PubMed Web of Science ®Google Scholar
• Neto AS, Wroclavski ML, Freire Pinto JL. Methodological standardization for the extraction of free DNA in plasma of peripheral blood. J Cancer Sci Ther. 2012;1(S5):2.
   Google Scholar
• O’Connell GC, Chantler PD, Barr TL. High interspecimen variability in nucleic acid extraction efficiency necessitates the use of spike-in control for accurate qPCR-based measurement of plasma cell-free DNA levels. Lab Med. 2017;48(4):332–338.
   PubMed Web of Science ®Google Scholar
• Ordoñez E, Rueda L, Cañadas MP, et al. Evaluation of sample stability and automated DNA extraction for fetal sex determination using cell-free fetal DNA in maternal plasma. BioMed Res Int. 2013;2013:195363.
   PubMed Web of Science ®Google Scholar
• Pérez-Barrios C, Nieto-Alcolado I, Torrente M, et al. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. Transl Lung Cancer Res. 2016;5(6):665–672.
   PubMed Web of Science ®Google Scholar
• Sorber L, Zwaenepoel K, Jacobs J, et al. Circulating cell-free DNA and RNA analysis as liquid biopsy: optimal centrifugation protocol. Cancers (Basel). 2019;11(4):458.
   PubMed Web of Science ®Google Scholar
• Van Wijk IJ, De Hoon AC, Jurhawan R, et al. Detection of apoptotic fetal cells in plasma of pregnant women. Clin Chem. 2000;46(5):729–731.
   PubMed Web of Science ®Google Scholar
• Page K, Powles T, Slade MJ, et al. The importance of careful blood processing in isolation of cell-free DNA. Ann NY Acad Sci. 2006;1075(1):313–317.
   PubMedGoogle Scholar
• Herrera LJ, Raja S, Gooding WE, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem. 2005;51(1):113–118.
   PubMed Web of Science ®Google Scholar
• Page K, Guttery DS, Zahra N, et al. Influence of plasma processing on recovery and analysis of circulating nucleic acids. PLoS One. 2013;8(10):e77963.
   PubMed Web of Science ®Google Scholar
• Rikkert LG, van der Pol E, van Leeuwen TG, et al. Centrifugation affects the purity of liquid biopsy-based tumor biomarkers. Cytometry. 2018;93(12):1207–1212.
   PubMedGoogle Scholar
• Kopreski MS, Benko FA, Kwee C, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer. 1997;76(10):1293–1299.
   PubMed Web of Science ®Google Scholar
• Sozzi G, Roz L, Conte D, et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Nat Cancer Inst. 2005;97(24):1848–1850.
   PubMedGoogle Scholar
• Lippi G, Guidi GC, Mattiuzzi C, et al. Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med. 2006;44(4):358–365.
   PubMed Web of Science ®Google Scholar
• Dimeski G. Interference testing. Clin Biochem Rev. 2008;29(Suppl. 1):S43–S48.
   PubMedGoogle Scholar
• Zhang Z, Zhu M, Chen Z, et al. Coaxial sensing bio-amplifier for ultrasensitive detections of circulating tumor DNAs. Biosens Bioelectron. 2019;141:111414.
   PubMed Web of Science ®Google Scholar
• Das J, Kelley SO. High-performance nucleic acid sensors for liquid biopsy applications. Angew Chem Int Ed. 2020;59(7):2554–2564.
   PubMed Web of Science ®Google Scholar
• Lee H, Na W, Park C, et al. Centrifugation-free extraction of circulating nucleic acids using immiscible liquid under vacuum pressure. Sci Rep. 2018;8(1):5467.
   PubMedGoogle Scholar
• Jeon SH, Lee HJ, Bae K, et al. Efficient capture and isolation of tumor-related circulating cell-free DNA from cancer patients using electroactive conducting polymer nanowire platforms. Theranostics. 2016;6(6):828–836.
   PubMed Web of Science ®Google Scholar
• Devonshire AS, Whale AS, Gutteridge A, et al. Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem. 2014;406(26):6499–6512.
   PubMed Web of Science ®Google Scholar
• Sato A, Nakashima C, Abe T, et al. Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. Oncotarget. 2018;9(61):31904–31914.
   PubMedGoogle Scholar
• Tsui DW, Barnett E, Scher HI. Toward standardization of preanalytical procedures for cell-free DNA profiling. Clin Chem. 2020;66(1):3–5.
   PubMed Web of Science ®Google Scholar
• Malentacchi F, Pazzagli M, Simi L, et al. SPIDIA-DNA: an external quality assessment for the pre-analytical phase of blood samples used for DNA-based analyses. Clin Chim Acta. 2013;424:274–286.
   PubMed Web of Science ®Google Scholar
• Lampignano R, Neumann MHD, Weber S, et al. Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows. Clin Chem. 2020;66(1):149–160.
   PubMed Web of Science ®Google Scholar
• Geeurickx E, Hendrix A. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Mol Aspects Med. 2020;72:100828.
   PubMed Web of Science ®Google Scholar
• Ammerlaan W, Betsou F. Biospecimen science of blood for cfDNA genetic analyses. Curr Pathobiol Rep. 2019;7(2):9–15.
   Google Scholar
• Dagher G, Becker KF, Bonin S, et al. Pre-analytical processes in medical diagnostics: new regulatory requirements and standards. New Biotechnol. 2019;52:121–125.
   PubMed Web of Science ®Google Scholar